Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Who cares? Everyone knows Micheal L. Robinson is pretending to be the first lady BUT why show up displaying male pattern baldness on a cooking show and 2 DAYS later wearing his shoulder length wig at a Black girls rock gig. Coming out of the White House closet now. Big mistake that don't make sense.
Its more than that, guaranteed. Next year it will be between 60-88% and I will be laughing all the way to to bank.
Why did that FREAK Michael Robinson show up on a cooking show BALD..
It was 2 cents after the most ethical CEO in mankind pulled a 100-1 REVERSE SPLIT on those who invested their hard earned money into his company. That left only 20 million O/S after that ethical action. Amount of shares 6 months later, anyone ?
Disclosure, I have to holdings. Just following and learning for future reference
Wouldn't work for me. I am allergic to cow stomach
Those 2 companies would be on my list Let's go CTIX..eom
Tombrady, couldn't agree more. NASDAQ listing alone means nothing without substantial follow through from the company. They need name association with a well recognized big pharma to be noticed. The astounding phase 2 Brilacidin results are met with media SILENCE while a mythical Teixobactin garners multiple front page news around the world . Absolutely Sickening. How many great posters on this board have contacted other researchers only to be told " I never heard of the company", " I lost track about the pipeline after the poly bankruptcy", They never heard of Brilacidin" and so on and so on. I still think the PPS goes up nicely by years end. Hopefully I am completely wrong and the entire medical community learns about and clamours for the CTIX pipeline drugs but so far the silence is deafening. I think most everyone on the board would be smiling if Monday morning headline states J and J in collaboration with CTIX are entering in multiple studies using revolutionary antibiotic Brilacidin. You get name recognition, financial security, and a sales team in one shot. Then I predict the PPS goes up dramatically because management will get a good deal. Deciding what to buy with the abundance of riches down the road would be the next step as a CTIX investor.
I hope the shelve registration never takes effect.
Have a good weekend all.
A good partnership deal with a well known big pharma and everyone can sleep soundly. Financial stability and having a big player backing their work would bring the credibility to end all speculation with the companies future. Until then......
WSJ causing roller coaster faces ..lol
Sentiment of the day
The risk is removed with good partnership deal..eom
Would a over the counter or even a scripted drug with no side effects used as a cancer preventative sell ? A drug use as a booster to keep the body cancer free. A ounce of Krevention is better than a pound of cure.
Capitulation today ?
Does CTIX have a cure for Deuteranopia ?
I seem to have lost the capability to see the color green about 2 weeks ago.
Might as well say it first. "Expect good things from Cellceutix next week"
Stock with a bright future
Cellceutix yearly progress
2011
Q1 2011 Market Cap 36.58 MM
2012
Q1 2012 Market Cap 47.55 MM
October 8 2012 Initiates the Phase I D-F trials for Kevetrin
2013
Q1 2013 Market Cap 165.52 MM
June 3 2013 Presented poster ASCO Kevetrin
June 17 2013 Stability test for Purisol tablets
September 15 2013 Aquires Polymedix
October 2 2013 IND new Psoriasis drug Prurisol
2014
February 24 2014 Brilacidin ophthalmic and otitis formulations started
February 25 2014 First patients 2b ABSSI enrolled
March 19 2014 Seventh cohort for Kevetrin initiated
March 24 2014 Initiates clinical trials for Prurisol
Q1 2014 Market Cap 173.64
May 5 2014 Prurisol completes first cohort
June 16 2014 Eight cohort entering for Kevetrin
July 18 2014 Breakthrough formulation for Brilacidin
Aug 07 2014 Prurisol primary end point met
Sept 19 2014 IND filed Brilacidin OM
Oct 23 2014 IND Brilacidin OM becomes effective
Oct 31 2014 Positive Top Line data regarding Brilicidin phII b
December 10 2014 Brilacidin QIPD designation
December 22 2014 Psoriasis FDA aproves initiation phII
Q1 2015 Market Cap 400 +
Jan 05 2015 Brilacidin confidence intervals revealed
Jan 20 2015 Kevetrin 10th cohort commenced 450mg/m2
Jan 26 2015 Meeting lawyers for Nasdaq listing. New pre-IND for gastrointestinal decease. FDA meeting requested
CTIX upcoming events within weeks
1) Much awaited P21 data reported through 10th cohort.
2) 10th cohort completion and launch of super potent 11th (likely MTD).
3) Add'l Brilacidin data compiled and submitted to FDA.
4) Phase 3 B-ABSSSI meeting and trial approval.
5) Fast Track/Priority Review/5 Yr exclus. approval stemming from meeting.
6) Nasdaq Capital Market Uplisting approval and transition.
7) Stellar and reputable BOD announcements
8) B-OM trial UP and RUNNING!!!
9) Ulcerative Proctitis pre-IND FDA meeting
10) Prurisol Phase 2 Trial Commencement (unclear, but quite possible).
11) Coverage initiation (strong buy) by one or more institutional research analysts.
12) And controversially, but biggest of all, some sort of BIG PHARMA partnership deal for Brilacidin post FDA Meeting.
Stock with a bright future
Cellceutix yearly progress
2011
Q1 2011 Market Cap 36.58 MM
2012
Q1 2012 Market Cap 47.55 MM
October 8 2012 Initiates the Phase I D-F trials for Kevetrin
2013
Q1 2013 Market Cap 165.52 MM
June 3 2013 Presented poster ASCO Kevetrin
June 17 2013 Stability test for Purisol tablets
September 15 2013 Aquires Polymedix
October 2 2013 IND new Psoriasis drug Prurisol
2014
February 24 2014 Brilacidin ophthalmic and otitis formulations started
February 25 2014 First patients 2b ABSSI enrolled
March 19 2014 Seventh cohort for Kevetrin initiated
March 24 2014 Initiates clinical trials for Prurisol
Q1 2014 Market Cap 173.64
May 5 2014 Prurisol completes first cohort
June 16 2014 Eight cohort entering for Kevetrin
July 18 2014 Breakthrough formulation for Brilacidin
Aug 07 2014 Prurisol primary end point met
Sept 19 2014 IND filed Brilacidin OM
Oct 23 2014 IND Brilacidin OM becomes effective
Oct 31 2014 Positive Top Line data regarding Brilicidin phII b
December 10 2014 Brilacidin QIPD designation
December 22 2014 Psoriasis FDA aproves initiation phII
Q1 2015 Market Cap 400 +
Jan 05 2015 Brilacidin confidence intervals revealed
Jan 20 2015 Kevetrin 10th cohort commenced 450mg/m2
Jan 26 2015 Meeting lawyers for Nasdaq listing. New pre-IND for gastrointestinal decease. FDA meeting requested
CTIX upcoming events within weeks
1) Much awaited P21 data reported through 10th cohort.
2) 10th cohort completion and launch of super potent 11th (likely MTD).
3) Add'l Brilacidin data compiled and submitted to FDA.
4) Phase 3 B-ABSSSI meeting and trial approval.
5) Fast Track/Priority Review/5 Yr exclus. approval stemming from meeting.
6) Nasdaq Capital Market Uplisting approval and transition.
7) Stellar and reputable BOD announcements
8) B-OM trial UP and RUNNING!!!
9) Ulcerative Proctitis pre-IND FDA meeting
10) Prurisol Phase 2 Trial Commencement (unclear, but quite possible).
11) Coverage initiation (strong buy) by one or more institutional research analysts.
12) And controversially, but biggest of all, some sort of BIG PHARMA partnership deal for Brilacidin post FDA Meeting.
Finally someone who tells the truth
Cellceutix Advancing Treatment for Hidradenitis Suppurativa, Pre-IND Meeting Request to Food and Drug Administration
BEVERLY, MA--(Marketwired - Mar 16, 2015)-Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to inform shareholders that further to the Company’s press release on March 2, 2015, Cellceutix is this week submitting a request with the U.S. Food and Drug Administration for a pre-Investigational New Drug (IND) meeting to initiate a clinical study for one of the Company’s Host Defense Proteins (HDPs) for the treatment of hidradenitis suppurativa (HS).
Hidradenitis suppurativa (also known as acne inversa) is a chronic and debilitating inflammatory skin disease characterized by recurrent abscesses and formation of sinus tracts, typically where skin rubs together, such as the armpits, groin, between the buttocks and under the breasts. Although the first published case was 176 years ago, the etiology of HS, which causes significant physical and psychosocial distress to both men and women, remains largely understood with no cure and only limited effective treatment options. Reports of prevalence range widely from approximately one-half a percent up to approximately four percent of the general population.
“Our team continues to analyze very promising data on our HDP mimetic for HS and we are excited to be moving ahead with this indication, commented Dr. Krishna Menon, Chief Scientific Officer at Cellceutix. “HS presents in many different forms and it is unclear the exact role of bacteria in the pathogenesis of HS, but a number of hard-to-treat bacteria species (i.e. Staphylococcus, Streptococcus, enterobacteriaceae) are commonly isolated in HS lesions, many of which our novel HDPs have been shown to be active against. We look forward to a meeting with the FDA in preparation for an IND filing and clinical study to treat this condition that plagues so many people.”
In other corporate developments, Cellceutix is also pleased to inform shareholders that Nasdaq has responded to the Company with a “request for additional information” regarding Cellceutix’s application to be listed on the Nasdaq exchange. Cellceutix executives and legal counsel are preparing the requisite information as requested as part of the move to uplist to Nasdaq.
With respect to the Phase 1 clinical trial of Kevetrin for solid tumors being conducted at Harvard’s Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center, the third and final patient in the tenth cohort is now enrolled and being treated with 450 mg/m2. Two patients have completed the dosing protocol with no serious adverse events reported to date. Further, samples have been taken from these subjects and sent to the laboratory for analysis of increased levels of the protein p21, a key biomarker for activity of p53, a protein often referred to as the “Guardian Angel of the Human Genome” because of its role as a master cell regulator and tumor suppressor.
“We are exhilarated for our company and shareholders as the ball is now rolling with respect to our move to Nasdaq. Our team is eagerly putting together the requested information to respond as quickly as possible,” commented Leo Ehrlich, Chief Executive Officer at Cellceutix. “As far as the Kevetrin trial, we believed that the severe weather conditions recently in the Boston area would have a more profound impact on treating patients. We are very happy to be advised that two patients have completed the treatment per protocol and the final patient in the cohort has been enrolled. We are aiming for a major breakthrough to treat certain types of cancer and greatly look forward to data on the p21 biomarker for patients treated at these higher dosing levels, which we are hopeful will support earlier data from the trial showing that increasing levels of p21 are dose dependent.”
Elsewhere in the pipeline, Cellceutix is also now engaged in scaling up the manufacturing of its lead Gram-negative compound for treating Klebsiella species and Escherichia coli (E. coli). Grant money studies are ongoing and data is expected in approximately one month, which will be used for planning clinical research. To expedite the Company’s Gram-negative program, Cellceutix is improving the manufacturing process of this very unique HDP mimetic.
Cellceutix intends to provide shareholders with a comprehensive update on all clinical trials and development of compounds in the pipeline following the end of the quarter.
About Cellceutix:
Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antimicrobial applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix will soon begin a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol has recently completed a Phase 1 clinical trial and is being readied for a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com.
Cellceutix Advancing Treatment for Hidradenitis Suppurativa, Pre-IND Meeting Request to Food and Drug Administration
BEVERLY, MA--(Marketwired - Mar 16, 2015)-Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, and antimicrobial applications, is pleased to inform shareholders that further to the Company’s press release on March 2, 2015, Cellceutix is this week submitting a request with the U.S. Food and Drug Administration for a pre-Investigational New Drug (IND) meeting to initiate a clinical study for one of the Company’s Host Defense Proteins (HDPs) for the treatment of hidradenitis suppurativa (HS).
Hidradenitis suppurativa (also known as acne inversa) is a chronic and debilitating inflammatory skin disease characterized by recurrent abscesses and formation of sinus tracts, typically where skin rubs together, such as the armpits, groin, between the buttocks and under the breasts. Although the first published case was 176 years ago, the etiology of HS, which causes significant physical and psychosocial distress to both men and women, remains largely understood with no cure and only limited effective treatment options. Reports of prevalence range widely from approximately one-half a percent up to approximately four percent of the general population.
“Our team continues to analyze very promising data on our HDP mimetic for HS and we are excited to be moving ahead with this indication, commented Dr. Krishna Menon, Chief Scientific Officer at Cellceutix. “HS presents in many different forms and it is unclear the exact role of bacteria in the pathogenesis of HS, but a number of hard-to-treat bacteria species (i.e. Staphylococcus, Streptococcus, enterobacteriaceae) are commonly isolated in HS lesions, many of which our novel HDPs have been shown to be active against. We look forward to a meeting with the FDA in preparation for an IND filing and clinical study to treat this condition that plagues so many people.”
In other corporate developments, Cellceutix is also pleased to inform shareholders that Nasdaq has responded to the Company with a “request for additional information” regarding Cellceutix’s application to be listed on the Nasdaq exchange. Cellceutix executives and legal counsel are preparing the requisite information as requested as part of the move to uplist to Nasdaq.
With respect to the Phase 1 clinical trial of Kevetrin for solid tumors being conducted at Harvard’s Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center, the third and final patient in the tenth cohort is now enrolled and being treated with 450 mg/m2. Two patients have completed the dosing protocol with no serious adverse events reported to date. Further, samples have been taken from these subjects and sent to the laboratory for analysis of increased levels of the protein p21, a key biomarker for activity of p53, a protein often referred to as the “Guardian Angel of the Human Genome” because of its role as a master cell regulator and tumor suppressor.
“We are exhilarated for our company and shareholders as the ball is now rolling with respect to our move to Nasdaq. Our team is eagerly putting together the requested information to respond as quickly as possible,” commented Leo Ehrlich, Chief Executive Officer at Cellceutix. “As far as the Kevetrin trial, we believed that the severe weather conditions recently in the Boston area would have a more profound impact on treating patients. We are very happy to be advised that two patients have completed the treatment per protocol and the final patient in the cohort has been enrolled. We are aiming for a major breakthrough to treat certain types of cancer and greatly look forward to data on the p21 biomarker for patients treated at these higher dosing levels, which we are hopeful will support earlier data from the trial showing that increasing levels of p21 are dose dependent.”
Elsewhere in the pipeline, Cellceutix is also now engaged in scaling up the manufacturing of its lead Gram-negative compound for treating Klebsiella species and Escherichia coli (E. coli). Grant money studies are ongoing and data is expected in approximately one month, which will be used for planning clinical research. To expedite the Company’s Gram-negative program, Cellceutix is improving the manufacturing process of this very unique HDP mimetic.
Cellceutix intends to provide shareholders with a comprehensive update on all clinical trials and development of compounds in the pipeline following the end of the quarter.
About Cellceutix:
Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antimicrobial applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix will soon begin a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol has recently completed a Phase 1 clinical trial and is being readied for a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com.
Stock with a bright future
Cellceutix yearly progress
2011
Q1 2011 Market Cap 36.58 MM
2012
Q1 2012 Market Cap 47.55 MM
October 8 2012 Initiates the Phase I D-F trials for Kevetrin
2013
Q1 2013 Market Cap 165.52 MM
June 3 2013 Presented poster ASCO Kevetrin
June 17 2013 Stability test for Purisol tablets
September 15 2013 Aquires Polymedix
October 2 2013 IND new Psoriasis drug Prurisol
2014
February 24 2014 Brilacidin ophthalmic and otitis formulations started
February 25 2014 First patients 2b ABSSI enrolled
March 19 2014 Seventh cohort for Kevetrin initiated
March 24 2014 Initiates clinical trials for Prurisol
Q1 2014 Market Cap 173.64
May 5 2014 Prurisol completes first cohort
June 16 2014 Eight cohort entering for Kevetrin
July 18 2014 Breakthrough formulation for Brilacidin
Aug 07 2014 Prurisol primary end point met
Sept 19 2014 IND filed Brilacidin OM
Oct 23 2014 IND Brilacidin OM becomes effective
Oct 31 2014 Positive Top Line data regarding Brilicidin phII b
December 10 2014 Brilacidin QIPD designation
December 22 2014 Psoriasis FDA aproves initiation phII
Q1 2015 Market Cap 400 +
Jan 05 2015 Brilacidin confidence intervals revealed
Jan 20 2015 Kevetrin 10th cohort commenced 450mg/m2
Jan 26 2015 Meeting lawyers for Nasdaq listing. New pre-IND for gastrointestinal decease. FDA meeting requested
CTIX upcoming events within weeks
1) Much awaited P21 data reported through 10th cohort.
2) 10th cohort completion and launch of super potent 11th (likely MTD).
3) Add'l Brilacidin data compiled and submitted to FDA.
4) Phase 3 B-ABSSSI meeting and trial approval.
5) Fast Track/Priority Review/5 Yr exclus. approval stemming from meeting.
6) Nasdaq Capital Market Uplisting approval and transition.
7) Stellar and reputable BOD announcements
8) B-OM trial UP and RUNNING!!!
9) Ulcerative Proctitis pre-IND FDA meeting
10) Prurisol Phase 2 Trial Commencement (unclear, but quite possible).
11) Coverage initiation (strong buy) by one or more institutional research analysts.
12) And controversially, but biggest of all, some sort of BIG PHARMA partnership deal for Brilacidin post FDA Meeting.
Idea of the year
Cellceutix yearly progress
2011
Q1 2011 Market Cap 36.58 MM
2012
Q1 2012 Market Cap 47.55 MM
October 8 2012 Initiates the Phase I D-F trials for Kevetrin
2013
Q1 2013 Market Cap 165.52 MM
June 3 2013 Presented poster ASCO Kevetrin
June 17 2013 Stability test for Purisol tablets
September 15 2013 Aquires Polymedix
October 2 2013 IND new Psoriasis drug Prurisol
2014
February 24 2014 Brilacidin ophthalmic and otitis formulations started
February 25 2014 First patients 2b ABSSI enrolled
March 19 2014 Seventh cohort for Kevetrin initiated
March 24 2014 Initiates clinical trials for Prurisol
Q1 2014 Market Cap 173.64
May 5 2014 Prurisol completes first cohort
June 16 2014 Eight cohort entering for Kevetrin
July 18 2014 Breakthrough formulation for Brilacidin
Aug 07 2014 Prurisol primary end point met
Sept 19 2014 IND filed Brilacidin OM
Oct 23 2014 IND Brilacidin OM becomes effective
Oct 31 2014 Positive Top Line data regarding Brilicidin phII b
December 10 2014 Brilacidin QIPD designation
December 22 2014 Psoriasis FDA aproves initiation phII
Q1 2015 Market Cap 400 +
Jan 05 2015 Brilacidin confidence intervals revealed
Jan 20 2015 Kevetrin 10th cohort commenced 450mg/m2
Jan 26 2015 Meeting lawyers for Nasdaq listing. New pre-IND for gastrointestinal decease. FDA meeting requested
CTIX upcoming events within weeks
1) Much awaited P21 data reported through 10th cohort.
2) 10th cohort completion and launch of super potent 11th (likely MTD).
3) Add'l Brilacidin data compiled and submitted to FDA.
4) Phase 3 B-ABSSSI meeting and trial approval.
5) Fast Track/Priority Review/5 Yr exclus. approval stemming from meeting.
6) Nasdaq Capital Market Uplisting approval and transition.
7) Stellar and reputable BOD announcements
8) B-OM trial UP and RUNNING!!!
9) Ulcerative Proctitis pre-IND FDA meeting
10) Prurisol Phase 2 Trial Commencement (unclear, but quite possible).
11) Coverage initiation (strong buy) by one or more institutional research analysts.
12) And controversially, but biggest of all, some sort of BIG PHARMA partnership deal for Brilacidin post FDA Meeting.
Under 5, applied Feb 5 for Nasdaq
Blockbuster
Cellceutix yearly progress
2011
Q1 2011 Market Cap 36.58 MM
2012
Q1 2012 Market Cap 47.55 MM
October 8 2012 Initiates the Phase I D-F trials for Kevetrin
2013
Q1 2013 Market Cap 165.52 MM
June 3 2013 Presented poster ASCO Kevetrin
June 17 2013 Stability test for Purisol tablets
September 15 2013 Aquires Polymedix
October 2 2013 IND new Psoriasis drug Prurisol
2014
February 24 2014 Brilacidin ophthalmic and otitis formulations started
February 25 2014 First patients 2b ABSSI enrolled
March 19 2014 Seventh cohort for Kevetrin initiated
March 24 2014 Initiates clinical trials for Prurisol
Q1 2014 Market Cap 173.64
May 5 2014 Prurisol completes first cohort
June 16 2014 Eight cohort entering for Kevetrin
July 18 2014 Breakthrough formulation for Brilacidin
Aug 07 2014 Prurisol primary end point met
Sept 19 2014 IND filed Brilacidin OM
Oct 23 2014 IND Brilacidin OM becomes effective
Oct 31 2014 Positive Top Line data regarding Brilicidin phII b
December 10 2014 Brilacidin QIPD designation
December 22 2014 Psoriasis FDA aproves initiation phII
Q1 2015 Market Cap 400 +
Jan 05 2015 Brilacidin confidence intervals revealed
Jan 20 2015 Kevetrin 10th cohort commenced 450mg/m2
Jan 26 2015 Meeting lawyers for Nasdaq listing. New pre-IND for gastrointestinal decease. FDA meeting requested
CTIX upcoming events within weeks
1) Much awaited P21 data reported through 10th cohort.
2) 10th cohort completion and launch of super potent 11th (likely MTD).
3) Add'l Brilacidin data compiled and submitted to FDA.
4) Phase 3 B-ABSSSI meeting and trial approval.
5) Fast Track/Priority Review/5 Yr exclus. approval stemming from meeting.
6) Nasdaq Capital Market Uplisting approval and transition.
7) Stellar and reputable BOD announcements
8) B-OM trial UP and RUNNING!!!
9) Ulcerative Proctitis pre-IND FDA meeting
10) Prurisol Phase 2 Trial Commencement (unclear, but quite possible).
11) Coverage initiation (strong buy) by one or more institutional research analysts.
12) And controversially, but biggest of all, some sort of BIG PHARMA partnership deal for Brilacidin post FDA Meeting.
Best under $5 potential
Cellceutix yearly progress
2011
Q1 2011 Market Cap 36.58 MM
2012
Q1 2012 Market Cap 47.55 MM
October 8 2012 Initiates the Phase I D-F trials for Kevetrin
2013
Q1 2013 Market Cap 165.52 MM
June 3 2013 Presented poster ASCO Kevetrin
June 17 2013 Stability test for Purisol tablets
September 15 2013 Aquires Polymedix
October 2 2013 IND new Psoriasis drug Prurisol
2014
February 24 2014 Brilacidin ophthalmic and otitis formulations started
February 25 2014 First patients 2b ABSSI enrolled
March 19 2014 Seventh cohort for Kevetrin initiated
March 24 2014 Initiates clinical trials for Prurisol
Q1 2014 Market Cap 173.64
May 5 2014 Prurisol completes first cohort
June 16 2014 Eight cohort entering for Kevetrin
July 18 2014 Breakthrough formulation for Brilacidin
Aug 07 2014 Prurisol primary end point met
Sept 19 2014 IND filed Brilacidin OM
Oct 23 2014 IND Brilacidin OM becomes effective
Oct 31 2014 Positive Top Line data regarding Brilicidin phII b
December 10 2014 Brilacidin QIPD designation
December 22 2014 Psoriasis FDA aproves initiation phII
Q1 2015 Market Cap 400 +
Jan 05 2015 Brilacidin confidence intervals revealed
Jan 20 2015 Kevetrin 10th cohort commenced 450mg/m2
Jan 26 2015 Meeting lawyers for Nasdaq listing. New pre-IND for gastrointestinal decease. FDA meeting requested
CTIX upcoming events within weeks
1) Much awaited P21 data reported through 10th cohort.
2) 10th cohort completion and launch of super potent 11th (likely MTD).
3) Add'l Brilacidin data compiled and submitted to FDA.
4) Phase 3 B-ABSSSI meeting and trial approval.
5) Fast Track/Priority Review/5 Yr exclus. approval stemming from meeting.
6) Nasdaq Capital Market Uplisting approval and transition.
7) Stellar and reputable BOD announcements
8) B-OM trial UP and RUNNING!!!
9) Ulcerative Proctitis pre-IND FDA meeting
10) Prurisol Phase 2 Trial Commencement (unclear, but quite possible).
11) Coverage initiation (strong buy) by one or more institutional research analysts.
12) And controversially, but biggest of all, some sort of BIG PHARMA partnership deal for Brilacidin post FDA Meeting.
Blockbuster
Cellceutix yearly progress
2011
Q1 2011 Market Cap 36.58 MM
2012
Q1 2012 Market Cap 47.55 MM
October 8 2012 Initiates the Phase I D-F trials for Kevetrin
2013
Q1 2013 Market Cap 165.52 MM
June 3 2013 Presented poster ASCO Kevetrin
June 17 2013 Stability test for Purisol tablets
September 15 2013 Aquires Polymedix
October 2 2013 IND new Psoriasis drug Prurisol
2014
February 24 2014 Brilacidin ophthalmic and otitis formulations started
February 25 2014 First patients 2b ABSSI enrolled
March 19 2014 Seventh cohort for Kevetrin initiated
March 24 2014 Initiates clinical trials for Prurisol
Q1 2014 Market Cap 173.64
May 5 2014 Prurisol completes first cohort
June 16 2014 Eight cohort entering for Kevetrin
July 18 2014 Breakthrough formulation for Brilacidin
Aug 07 2014 Prurisol primary end point met
Sept 19 2014 IND filed Brilacidin OM
Oct 23 2014 IND Brilacidin OM becomes effective
Oct 31 2014 Positive Top Line data regarding Brilicidin phII b
December 10 2014 Brilacidin QIPD designation
December 22 2014 Psoriasis FDA aproves initiation phII
Q1 2015 Market Cap 400 +
Jan 05 2015 Brilacidin confidence intervals revealed
Jan 20 2015 Kevetrin 10th cohort commenced 450mg/m2
Jan 26 2015 Meeting lawyers for Nasdaq listing. New pre-IND for gastrointestinal decease. FDA meeting requested
CTIX upcoming events within weeks
1) Much awaited P21 data reported through 10th cohort.
2) 10th cohort completion and launch of super potent 11th (likely MTD).
3) Add'l Brilacidin data compiled and submitted to FDA.
4) Phase 3 B-ABSSSI meeting and trial approval.
5) Fast Track/Priority Review/5 Yr exclus. approval stemming from meeting.
6) Nasdaq Capital Market Uplisting approval and transition.
7) Stellar and reputable BOD announcements
8) B-OM trial UP and RUNNING!!!
9) Ulcerative Proctitis pre-IND FDA meeting
10) Prurisol Phase 2 Trial Commencement (unclear, but quite possible).
11) Coverage initiation (strong buy) by one or more institutional research analysts.
12) And controversially, but biggest of all, some sort of BIG PHARMA partnership deal for Brilacidin post FDA Meeting.
Coming stock of the year
Cellceutix yearly progress
2011
Q1 2011 Market Cap 36.58 MM
2012
Q1 2012 Market Cap 47.55 MM
October 8 2012 Initiates the Phase I D-F trials for Kevetrin
2013
Q1 2013 Market Cap 165.52 MM
June 3 2013 Presented poster ASCO Kevetrin
June 17 2013 Stability test for Purisol tablets
September 15 2013 Aquires Polymedix
October 2 2013 IND new Psoriasis drug Prurisol
2014
February 24 2014 Brilacidin ophthalmic and otitis formulations started
February 25 2014 First patients 2b ABSSI enrolled
March 19 2014 Seventh cohort for Kevetrin initiated
March 24 2014 Initiates clinical trials for Prurisol
Q1 2014 Market Cap 173.64
May 5 2014 Prurisol completes first cohort
June 16 2014 Eight cohort entering for Kevetrin
July 18 2014 Breakthrough formulation for Brilacidin
Aug 07 2014 Prurisol primary end point met
Sept 19 2014 IND filed Brilacidin OM
Oct 23 2014 IND Brilacidin OM becomes effective
Oct 31 2014 Positive Top Line data regarding Brilicidin phII b
December 10 2014 Brilacidin QIPD designation
December 22 2014 Psoriasis FDA aproves initiation phII
Q1 2015 Market Cap 400 +
Jan 05 2015 Brilacidin confidence intervals revealed
Jan 20 2015 Kevetrin 10th cohort commenced 450mg/m2
Jan 26 2015 Meeting lawyers for Nasdaq listing. New pre-IND for gastrointestinal decease. FDA meeting requested
CTIX upcoming events within weeks
1) Much awaited P21 data reported through 10th cohort.
2) 10th cohort completion and launch of super potent 11th (likely MTD).
3) Add'l Brilacidin data compiled and submitted to FDA.
4) Phase 3 B-ABSSSI meeting and trial approval.
5) Fast Track/Priority Review/5 Yr exclus. approval stemming from meeting.
6) Nasdaq Capital Market Uplisting approval and transition.
7) Stellar and reputable BOD announcements
8) B-OM trial UP and RUNNING!!!
9) Ulcerative Proctitis pre-IND FDA meeting
10) Prurisol Phase 2 Trial Commencement (unclear, but quite possible).
11) Coverage initiation (strong buy) by one or more institutional research analysts.
12) And controversially, but biggest of all, some sort of BIG PHARMA partnership deal for Brilacidin post FDA Meeting.
Green today...eom
Cellceutix GREAT progress
2011
Q1 2011 Market Cap 36.58 MM
2012
Q1 2012 Market Cap 47.55 MM
October 8 2012 Initiates the Phase I D-F trials for Kevetrin
2013
Q1 2013 Market Cap 165.52 MM
June 3 2013 Presented poster ASCO Kevetrin
June 17 2013 Stability test for Purisol tablets
September 15 2013 Aquires Polymedix
October 2 2013 IND new Psoriasis drug Prurisol
2014
February 24 2014 Brilacidin ophthalmic and otitis formulations started
February 25 2014 First patients 2b ABSSI enrolled
March 19 2014 Seventh cohort for Kevetrin initiated
March 24 2014 Initiates clinical trials for Prurisol
Q1 2014 Market Cap 173.64
May 5 2014 Prurisol completes first cohort
June 16 2014 Eight cohort entering for Kevetrin
July 18 2014 Breakthrough formulation for Brilacidin
Aug 07 2014 Prurisol primary end point met
Sept 19 2014 IND filed Brilacidin OM
Oct 23 2014 IND Brilacidin OM becomes effective
Oct 31 2014 Positive Top Line data regarding Brilicidin phII b
December 10 2014 Brilacidin QIPD designation
December 22 2014 Psoriasis FDA aproves initiation phII
Q1 2015 Market Cap 400 +
Jan 05 2015 Brilacidin confidence intervals revealed
Jan 20 2015 Kevetrin 10th cohort commenced 450mg/m2
Jan 26 2015 Meeting lawyers for Nasdaq listing. New pre-IND for gastrointestinal decease. FDA meeting requested
Cellceutix progress
2011
Q1 2011 Market Cap 36.58 MM
2012
Q1 2012 Market Cap 47.55 MM
October 8 2012 Initiates the Phase I D-F trials for Kevetrin
2013
Q1 2013 Market Cap 165.52 MM
June 3 2013 Presented poster ASCO Kevetrin
June 17 2013 Stability test for Purisol tablets
September 15 2013 Aquires Polymedix
October 2 2013 IND new Psoriasis drug Prurisol
2014
February 24 2014 Brilacidin ophthalmic and otitis formulations started
February 25 2014 First patients 2b ABSSI enrolled
March 19 2014 Seventh cohort for Kevetrin initiated
March 24 2014 Initiates clinical trials for Prurisol
Q1 2014 Market Cap 173.64
May 5 2014 Prurisol completes first cohort
June 16 2014 Eight cohort entering for Kevetrin
July 18 2014 Breakthrough formulation for Brilacidin
Aug 07 2014 Prurisol primary end point met
Sept 19 2014 IND filed Brilacidin OM
Oct 23 2014 IND Brilacidin OM becomes effective
Oct 31 2014 Positive Top Line data regarding Brilicidin phII b
December 10 2014 Brilacidin QIPD designation
December 22 2014 Psoriasis FDA aproves initiation phII
Q1 2015 Market Cap 400 +
Jan 05 2015 Brilacidin confidence intervals revealed
Jan 20 2015 Kevetrin 10th cohort commenced 450mg/m2
Jan 26 2015 Meeting lawyers for Nasdaq listing. New pre-IND for gastrointestinal decease. FDA meeting requested
Cellceutix yearly progress
2011
Q1 2011 Market Cap 36.58 MM
2012
Q1 2012 Market Cap 47.55 MM
October 8 2012 Initiates the Phase I D-F trials for Kevetrin
2013
Q1 2013 Market Cap 165.52 MM
June 3 2013 Presented poster ASCO Kevetrin
June 17 2013 Stability test for Purisol tablets
September 15 2013 Aquires Polymedix
October 2 2013 IND new Psoriasis drug Prurisol
2014
February 24 2014 Brilacidin ophthalmic and otitis formulations started
February 25 2014 First patients 2b ABSSI enrolled
March 19 2014 Seventh cohort for Kevetrin initiated
March 24 2014 Initiates clinical trials for Prurisol
Q1 2014 Market Cap 173.64
May 5 2014 Prurisol completes first cohort
June 16 2014 Eight cohort entering for Kevetrin
July 18 2014 Breakthrough formulation for Brilacidin
Aug 07 2014 Prurisol primary end point met
Sept 19 2014 IND filed Brilacidin OM
Oct 23 2014 IND Brilacidin OM becomes effective
Oct 31 2014 Positive Top Line data regarding Brilicidin phII b
December 10 2014 Brilacidin QIPD designation
December 22 2014 Psoriasis FDA aproves initiation phII
Q1 2015 Market Cap 400 +
Jan 05 2015 Brilacidin confidence intervals revealed
Jan 20 2015 Kevetrin 10th cohort commenced 450mg/m2
Jan 26 2015 Meeting lawyers for Nasdaq listing. New pre-IND for gastrointestinal decease. FDA meeting requested
I guess my faith in management is stronger than most . I don't see them filing paperwork with NASDAQ Feb 5 with the hopes of listing by year end. I anticipate they had their ducks in a row to complete the 4-6 week process during a period close to that time frame.
Go CTIX
Companies go by the fiscal year. Ending March 31st, starting April 1st.
Maybe, hopefully that is the time period mentioned.
CTIX upcoming events within weeks
1) Much awaited P21 data reported through 10th cohort.
2) 10th cohort completion and launch of super potent 11th (likely MTD).
3) Add'l Brilacidin data compiled and submitted to FDA.
4) Phase 3 B-ABSSSI meeting and trial approval.
5) Fast Track/Priority Review/5 Yr exclus. approval stemming from meeting.
6) Nasdaq Capital Market Uplisting approval and transition.
7) Stellar and reputable BOD announcements
8) B-OM trial UP and RUNNING!!!
9) Ulcerative Proctitis pre-IND FDA meeting
10) Prurisol Phase 2 Trial Commencement (unclear, but quite possible).
11) Coverage initiation (strong buy) by one or more institutional research analysts.
12) And controversially, but biggest of all, some sort of BIG PHARMA partnership deal for Brilacidin post FDA Meeting.
Agree, 4$ PLUS this week
Beautiful chart PLUS MORE !!!!!
CTIX upcoming events within weeks
1) Much awaited P21 data reported through 10th cohort.
2) 10th cohort completion and launch of super potent 11th (likely MTD).
3) Add'l Brilacidin data compiled and submitted to FDA.
4) Phase 3 B-ABSSSI meeting and trial approval.
5) Fast Track/Priority Review/5 Yr exclus. approval stemming from meeting.
6) Nasdaq Capital Market Uplisting approval and transition.
7) Stellar and reputable BOD announcements
8) B-OM trial UP and RUNNING!!!
9) Ulcerative Proctitis pre-IND FDA meeting
10) Prurisol Phase 2 Trial Commencement (unclear, but quite possible).
11) Coverage initiation (strong buy) by one or more institutional research analysts.
12) And controversially, but biggest of all, some sort of BIG PHARMA partnership deal for Brilacidin post FDA Meeting.
CTIX upcoming events within weeks
1) Much awaited P21 data reported through 10th cohort.
2) 10th cohort completion and launch of super potent 11th (likely MTD).
3) Add'l Brilacidin data compiled and submitted to FDA.
4) Phase 3 B-ABSSSI meeting and trial approval.
5) Fast Track/Priority Review/5 Yr exclus. approval stemming from meeting.
6) Nasdaq Capital Market Uplisting approval and transition.
7) Stellar and reputable BOD announcements
8) B-OM trial UP and RUNNING!!!
9) Ulcerative Proctitis pre-IND FDA meeting
10) Prurisol Phase 2 Trial Commencement (unclear, but quite possible).
11) Coverage initiation (strong buy) by one or more institutional research analysts.
12) And controversially, but biggest of all, some sort of BIG PHARMA partnership deal for Brilacidin post FDA Meeting.
Been posting since 1.90, now 3.85. What's r3algood is the curtains haven't even opened for the first act. Sit down, kick back and enjoy the show. The sky's the limit on this one.
CTIX upcoming events within weeks
1) Much awaited P21 data reported through 10th cohort.
2) 10th cohort completion and launch of super potent 11th (likely MTD).
3) Add'l Brilacidin data compiled and submitted to FDA.
4) Phase 3 B-ABSSSI meeting and trial approval.
5) Fast Track/Priority Review/5 Yr exclus. approval stemming from meeting.
6) Nasdaq Capital Market Uplisting approval and transition.
7) Stellar and reputable BOD announcements
8) B-OM trial UP and RUNNING!!!
9) Ulcerative Proctitis pre-IND FDA meeting
10) Prurisol Phase 2 Trial Commencement (unclear, but quite possible).
11) Coverage initiation (strong buy) by one or more institutional research analysts.
12) And controversially, but biggest of all, some sort of BIG PHARMA partnership deal for Brilacidin post FDA Meeting.
long term 10 bagger buy .
CTIX upcoming events within weeks
1) Much awaited P21 data reported through 10th cohort.
2) 10th cohort completion and launch of super potent 11th (likely MTD).
3) Add'l Brilacidin data compiled and submitted to FDA.
4) Phase 3 B-ABSSSI meeting and trial approval.
5) Fast Track/Priority Review/5 Yr exclus. approval stemming from meeting.
6) Nasdaq Capital Market Uplisting approval and transition.
7) Stellar and reputable BOD announcements
8) B-OM trial UP and RUNNING!!!
9) Ulcerative Proctitis pre-IND FDA meeting
10) Prurisol Phase 2 Trial Commencement (unclear, but quite possible).
11) Coverage initiation (strong buy) by one or more institutional research analysts.
12) And controversially, but biggest of all, some sort of BIG PHARMA partnership deal for Brilacidin post FDA Meeting.
Beautiful chart PLUS MORE
CTIX upcoming events within weeks
1) Much awaited P21 data reported through 10th cohort.
2) 10th cohort completion and launch of super potent 11th (likely MTD).
3) Add'l Brilacidin data compiled and submitted to FDA.
4) Phase 3 B-ABSSSI meeting and trial approval.
5) Fast Track/Priority Review/5 Yr exclus. approval stemming from meeting.
6) Nasdaq Capital Market Uplisting approval and transition.
7) Stellar and reputable BOD announcements
8) B-OM trial UP and RUNNING!!!
9) Ulcerative Proctitis pre-IND FDA meeting
10) Prurisol Phase 2 Trial Commencement (unclear, but quite possible).
11) Coverage initiation (strong buy) by one or more institutional research analysts.
12) And controversially, but biggest of all, some sort of BIG PHARMA partnership deal for Brilacidin post FDA Meeting.
Worth a long term buy .
CTIX upcoming events within weeks
1) Much awaited P21 data reported through 10th cohort.
2) 10th cohort completion and launch of super potent 11th (likely MTD).
3) Add'l Brilacidin data compiled and submitted to FDA.
4) Phase 3 B-ABSSSI meeting and trial approval.
5) Fast Track/Priority Review/5 Yr exclus. approval stemming from meeting.
6) Nasdaq Capital Market Uplisting approval and transition.
7) Stellar and reputable BOD announcements
8) B-OM trial UP and RUNNING!!!
9) Ulcerative Proctitis pre-IND FDA meeting
10) Prurisol Phase 2 Trial Commencement (unclear, but quite possible).
11) Coverage initiation (strong buy) by one or more institutional research analysts.
12) And controversially, but biggest of all, some sort of BIG PHARMA partnership deal for Brilacidin post FDA Meeting.